Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy for Down Syndrome Children with AML, MDS, or TMD
NCT00003593Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 1999
- Primary completion
- Mar 2007
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of cytarabine, daunorubicin, tioguanine, asparaginase escherichia coli in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), transient myeloproliferative disorder (TMD), sponsored by Children's Oncology Group. Started Jun 1999; status: completed.
02
Drugs
cytarabinedaunorubicintioguanineasparaginase escherichia coli
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)transient myeloproliferative disorder (TMD)
Beyond the preview
Go deeper on NCT00003593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003593.